The strategic decision to end further internal development of the ex-Novartis asset, dubbed naporafenib, will allow Erasca to ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

Atara Biotherapeutics continues to salami slice its head count, this time laying off 30% of what remains of the biopharma's ...

Leap Therapeutics is laying off half of its staff as the company narrows the focus of its lead cancer drug against the ...

Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, ...

Azafaros has secured 132 million euros ($147 million) in series B funds that the Dutch biotech will use to push its rare ...

North Carolina-based CRO Fortrea is saying goodbye to its CEO. | North Carolina-based CRO Fortrea is saying goodbye to its ...

The uncertainty around splitting up the business is only the latest in a series of strategic shake-ups at Galapagos in recent years. Other major events have included the pivot to CAR-Ts in 2022 and ...

CapsoVision has filed to go public, with plans to raise up to $30 million to support the development of its swallowable ...

The founder and former leader of Inhibikase Therapeutics is blazing a new biotech trail in an effort to get a beleaguered ...

California biotech NGM Bio is slimming down as the company pivots focus, shedding around 75% of staff, pausing development of ...

Biotech bank balances were again in focus Monday morning, with Tango Therapeutics cutting preclinical work to stretch its ...